Prosight Management, LP Macrogenics Inc Transaction History

Prosight Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$14.51 - $19.71 $1.56 Million - $2.12 Million	-107,560 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$11.11 - $25.6 $961,781 - $2.22 Million	-86,569 Reduced 44.59%	107,560 $1.93 Million
Q4 2018 Feb 14, 2019	SELL	$11.75 - $21.42 $3.09 Million - $5.64 Million	-263,346 Reduced 57.57%	194,129 $2.47 Million
Q3 2018 Nov 15, 2018	SELL	$19.26 - $23.46 $3.1 Million - $3.78 Million	-161,040 Reduced 26.04%	457,475 $9.81 Million
Q2 2018 Aug 14, 2018	BUY	$19.78 - $24.67 $3.43 Million - $4.28 Million	173,515 Added 38.99%	618,515 $12.8 Million
Q1 2018 May 14, 2018	SELL	$18.89 - $32.46 $3.07 Million - $5.28 Million	-162,696 Reduced 26.77%	445,000 $11.2 Million
Q4 2017 Feb 13, 2018	BUY	$16.19 - $20.3 $9.84 Million - $12.3 Million	607,696	607,696 $11.5 Million

134

55.5M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $199M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.